Compare Novo Nordisk A/S (NVO) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PPG Industries, Inc. — how do they compare? Novo Nordisk A/S trades at $46.22 (market cap $207.85B), while PPG Industries, Inc. trades at $114.82 (market cap $25.82B). The key difference: Novo Nordisk A/S is far larger — about 8× PPG Industries, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | PPG | |
|---|---|---|
Market Cap | $207.85B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $131.56 |
52-Week Low | $35.29 | $94.34 |
Enterprise Value | $222.55B | $31.69B |
Dividend Yield | 3.81% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
PPG Industries trades at $114.90, down 0.49% on the day, with mixed technical signals showing neutral momentum. The company maintains solid fundamentals with $15.88B in 2025 revenue, 9.57% net margin, and strong cash flow generation. Recent Q2 2026 earnings of $2.23 per share slightly missed expectations despite 7% sales growth. Analyst sentiment remains positive with 55% buy ratings and a $129.17 consensus price target representing 12% upside potential.
PPG offers attractive valuation with 16.67 P/E and dividend growth potential, but faces margin pressure from raw material costs. The stock presents a balanced opportunity for income and value investors, though macroeconomic headwinds and competitive pressures require monitoring. The recent dividend increase to $0.74 per share reinforces management's confidence in long-term cash flow stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
